Skip to content
PRME·Nasdaq·US

Prime Medicine

Prime Medicine is a biotechnology company developing genetic medicines based on its Prime Editing gene editing technology, aiming to provide durable or curative treatments for diseases driven by genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. It advances wholly owned in vivo programs targeting liver diseases and cystic fibrosis, as well as partnered ex vivo programs with Bristol-Myers Squibb, within the gene editing therapeutics industry.

Source: SEC 10-K Mar 3, 2026

Thematic Position

PRME

Relationship Groups

Customers1
Partners2
Licensing2
Competitors14

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

4 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

data restrictionnational securitysanction
DOJ rule restricts transfers of health and genetic data to China, Russia
SEC 10-KMar 3, 2026

The full regulatory passage is part of the Pro plan.

9 more · Regulatory and geopolitical insights are part of the Pro plan.